Cipla achieves record quarterly revenue, sees strong growth across key markets

Cipla Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2025, achieving its highest-ever quarterly revenue of INR 7,589 Cr. This represents an 8% year-over-year growth, with a net profit of INR 1,351 Cr, up 4% from Q2 FY25. The company’s consolidated EBITDA reached INR 1,895 Cr, showing a 0.5% increase.

The growth was primarily fueled by strong performances in One India, North America, and Emerging Markets & Europe. One India delivered INR 3,146 Cr revenue, up 7% YoY, with Foracort ranked as the #1 brand. North America contributed $233 Mn, with Albuterol leading its market segment. Emerging Markets & Europe recorded $110 Mn, reflecting a 15% increase. Cipla also announced a strategic collaboration with Eli Lilly for chronic care, introducing Yurpeak (Tirzepatide) in India.

The company's paid-up equity share capital increased to INR 161.55 Crores during the quarter due to ESOS and ESAR schemes. Cipla maintained a robust balance sheet with total debt at INR 467 Cr and cash and cash equivalents at INR 10,368 Cr. Its ESG rating was upgraded to 'A' from 'BBB' by MSCI, recognizing its energy transition and zero-fatality initiatives.